Conocimiento de la enfermedad asmática como factor protector de neumonía

Rodríguez, Francesc; Duran, Analía; Muñoz, Zulema; Serra-Prat, Mateu; Boixeda, Ramón; Ruiz, María Carmen.
Enferm. clín. (Ed. impr.) ; 30(2): 108-113, mar.-abr. 2020. tab
Artículo en Español | IBECS (España) | ID: ibc-193278

Documentos relacionados

  1. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
  2. BTS Clinical Statement on the prevention and management of community-acquired pneumonia in people with learning disability.
  3. Vitamin C for preventing and treating pneumonia.
  4. Levels of evidence supporting European and American community-acquired pneumonia guidelines.
  5. Review: In COPD, injectable polyvalent pneumococcal vaccines reduce risk for community-acquired pneumonia.
  6. Role of Statins in Treatment and Prevention of Community-acquired Pneumonia:A Meta-analysis.
  7. Collateral benefit of non-pharmacological interventions against COVID-19 to prevent community-acquired pneumonia in Jin-Shan, New Taipei, April to December 2020.
  8. The changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden.
  9. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.
  10. [Progress on the effectiveness of the pneumococcal vaccination in patients with chronic obstructive pulmonary disease].